首页> 外文期刊>Romanian Journal of Morphology and Embryology >Ductal invasive mammary carcinoma - clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2eu oncoprotein
【24h】

Ductal invasive mammary carcinoma - clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2eu oncoprotein

机译:导管浸润性乳腺癌-与激素受体和Her2 / neu癌蛋白的免疫组化表达相关的临床病理预后因素

获取原文
           

摘要

We analyzed 75 cases of invasive ductal mammary carcinoma type NOS and focused on comparative investigation of hormonal receptors (estrogen receptor ER and progesterone receptor PR) and Her2eu oncoprotein expression, according to which we ranked the cases in molecular classification subtypes, determining certain correlations between them and morphoclinical prognostic factors. 73.4% of cases were ER+ and 26.6% were ER-. PR was present in 62.6% of cases and absent in 37.4%. Phenotype ER+PR+ (58.6%) had the highest incidence, followed by ER-PR- (22.8%) and ER+PR- (14.6%). Phenotype ER-PR+ (4%) registered the lowest incidence. 14.8% of tumors were Her2eu + score 3+, 4% had equivocal score 2+ and 81.3% were negative Her2eu scored 0 and 1+. 9.5% of cases Her2eu positive scored 3+ were ER+PR+ and 88.5% of cases Her2eu negative scored 0-1 were ER+PR+. In terms of the correlation among the status of ER, PR and Her2eu, we determined a molecular classification of the cases, obtaining the following incidences: luminal A 70% of cases, basal 14.7% of cases, luminal B 8.3%, the lowest incidence being registered at Her2, 7% of cases. Luminal A and basal subtypes were associated with patients aged over 50 years (82% for luminal A and 90% for basal), whereas luminal B and Her2 subtypes were registered mostly at patients aged under 60-year-old (83% for luminal B and 100% for Her2). Luminal A subtype was characterized by small tumors (92% of cases were T1-T2), well and moderately differentiated tumors (58% of cases were G1-G2). 83.3% of cases in luminal B subtype had tumors with dimensions ranked T2-T3, all cases being moderately and low differentiated. Her2 subtype had T2-T3 tumors in 60% of cases, which were G3 low differentiated in a percent of 80%. The basal subtype mostly had tumors larger than 5 cm (91% of cases were T2-T3), out of which only a case (9%) presented well-differentiated G1.
机译:我们分析了75例NOS型浸润性导管癌,重点研究了激素受体(雌激素受体ER和孕激素受体PR)和Her2 / neu癌蛋白表达的比较研究,然后根据分子分类亚型对病例进行排名,确定了相关性它们与形态学预后因素之间的关系。 ER +占73.4%,ER-占26.6%。 PR占62.6%,不存在37.4%。表型ER + PR +(58.6%)发生率最高,其次是ER-PR-(22.8%)和ER + PR-(14.6%)。表型ER-PR +(4%)发生率最低。 14.8%的肿瘤为Her2 / neu +得分3+,4%的模棱两可得分为2+,81.3%的阴性Her2 / neu得分为0和1+。评分为3+的Her2 / neu阳性病例的9.5%为ER + PR +,评分为0-1的Her2 / neu阴性的病例为ER + PR +的88.5%。根据ER,PR和Her2 / neu的状态之间的相关性,我们确定了病例的分子分类,获得了以下发病率:管腔A占70%,基础14.7%,管腔B 8.3%,发生率最低的是Her2,占7%。发光体A和基底亚型与50岁以上的患者相关(腔A为82%,基底为90%),而腔B和Her2亚型大多发生在60岁以下的患者中(对于腔B为83%)和Her2的100%)。 Luminal A亚型的特征是小肿瘤(92%的病例是T1-T2),高分化的肿瘤(58%的病例是G1-G2)。腔B型亚型中83.3%的病例的肿瘤大小为T2-T3,所有病例均为中度和低分化。 Her2亚型在60%的病例中患有T2-T3肿瘤,其中G3低分化率为80%。基底亚型的肿瘤多于5 cm(91%的病例是T2-T3),其中只有1例(9%)的G1分化良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号